semaglutide

Wikidata

From sema- +‎ -glutide (“glucagon-like peptide analog”).

• Audio (General American):

  (file)

semaglutide (countable and uncountable, plural semaglutides)

2. (pharmacology) A peptide used in the treatment of diabetes and as an antiobesity medication.
   • 2022 April 28, Gina Kolata, “Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims”, in The New York Times‎^[1], →ISSN:

     Last year, the situation began to change when Novo Nordisk received approval from the Food and Drug Administration to market semaglutide. The drug can elicit a 15 percent to 17 percent weight loss in people with obesity.

   • 2023 February 23, Jason Halford, “It may be the most effective anti-obesity drug yet – but even Wegovy is no ‘wonder cure’”, in The Guardian‎^[2], →ISSN:

     But now a new generation of medications has arrived, based on a better understanding of the biological underpinnings of obesity. […] One of these medications – semaglutide, sold under the brand name Wegovy – will soon be available in UK chemists in the form of a weekly, self-administered injection.

   • 2023 May 19, Sarah Zhang, “Ozempic’s Next Act”, in The Atlantic‎^[3]:

     As semaglutide has skyrocketed in popularity, patients have been sharing curious effects that go beyond just appetite suppression. They have reported losing interest in a whole range of addictive and compulsive behaviors: drinking, smoking, shopping, biting nails, picking at skin.

   • 2024 April 20, Eshe Nelson, Charlotte de la Fuente, “It Introduced Ozempic to the World. Now It Must Remake Itself.”, in The New York Times‎^[4], →ISSN:

     The heart of the growth is semaglutide, Novo Nordisk’s synthetic version of a hormone known as glucagon-like peptide 1, or GLP-1, which helps the body regulate blood sugar levels.

• GLP-1 RA

• Ozempic, Wegovy, Rybelsus (brand names)

semaglutide m (countable and uncountable, plural semaglutides)

1. semaglutide: alternative form of sémaglutide